French multinational pharmaceutical and healthcare company Sanofi has announced a partnership with New York-based TrialSpark, providing a technology-driven model for drug development.
TrialSpark’s tools aim more efficient trial design, faster trial completion, and higher quality trial data. It buys clinical-stage drugs from pharmaceutical and biotech companies and develops them using its technology. The company’s treatment areas include rheumatology, dermatology, CNS (neurology and psychiatry) and cardiovascular diseases.
This partnership will focus on the acquisition or licensing and development of clinical phase II and phase III drug candidates in areas of high and unmet patient need.
The Sanofi and TrialSpark partnership will target six deals over three years. It aims to leverage Sanofi’s global commercial expertise and TrialSpark’s technology-driven drug development capabilities to explore new clinical development paradigms in areas such as behavioral interventions and technology. digital.
“We are delighted to begin this new partnership with TrialSpark, as another example of our commitment to innovation in the system,” said Alban de La Sabliere, head of partnerships at Sanofi. health care ecology”. “This partnership will not only identify attractive late-stage properties, but also utilize innovative development plans that can deliver meaningful outcomes for patients in areas of mutual interest.” care about.”
TREND TO BIGGER WOMAN
About a year ago TrialSpark hits $156 million in Series C . funding, bringing the company’s total raise to $250 million. At the time, the company said it was looking to buy or partner with pharmaceutical companies with assets at the clinical trial stage.
Sanofi has targeted drug detection into AI over the past year, announcing in January of a more than $100 million deal with the tech company. Exscientia.
That deal involved the generation of 15 new small-molecule candidates in oncology and immunology. Exscientia’s AI platform will be used in a variety of ways, including targeting and selecting patients.
Exscientia is eligible for payments of up to $5.2 billion for clinical development and regulatory and commercial milestones.
In addition, the digital chronic disease management company DarioHealth signed a $30 million strategic partnership with Sanofi to accelerate the adoption of Dario’s tools in the US market.
Sanofi has announced many other collaborations over the past year, including a partnership with Health2Sync.
